Interleukin-17A in Alzheimer's Disease: Recent Advances and Controversies.

Xin-Zhu Yan,Laijun Lai,Qiang Ao,Xiao-Hong Tian,Yan-Hui Zhang
DOI: https://doi.org/10.2174/1570159x19666210823110004
2022-01-01
Current Neuropharmacology
Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disease that mainly affects older adults. Although the global burden of AD is increasing year by year, the causes of AD remain largely unknown. Numerous basic and clinical studies have shown that interleukin-17A (IL-17A) may play a significant role in the pathogenesis of AD. A comprehensive assessment of the role of IL-17A in AD would benefit the diagnosis, understanding of etiology and treatment. However, over the past decade, controversies remain regarding the expression level and role of IL-17A in AD. We have incorporated newly published researches and point out that IL-17A expression levels may vary along with the development of AD, exercising different roles at different stages of AD, although much more work remains to be done to support the potential role of IL-17A in AD-related pathology. Here, it is our intention to review the underlying mechanisms of IL-17A in AD and address the current controversies in an effort to clarify the results of existing research and suggest future studies.
What problem does this paper attempt to address?